[PRNewswire] MGI and Bio-Medical Science Sign MOU
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"This MOU marks a key milestone for the development of genomics in South Korea as we introduce localized, high-quality and cost-effective solutions powered by our proprietary DNBSEQ™ technology." said Roy Tan, General Manager of MGI Asia Pacific. "By joining forces with our partner BMS, MGI aims to facilitate more widespread adoption of genomics, multi-omics, metagenomics and related business locally in South Korea."
"Amidst a rapidly growing high-throughput sequencing market in South Korea, we are noticing a mismatch between demand and supply and hope to eliminate access barriers by bringing products and solutions that are proven efficient, convenient and suited for local needs," said Kangsan D. Kim, Director of Marketing & Communications at BMS. "We are excited to partner with [PRNewswire] MGI to speed up the localization of their cutting-edge genomics products, especially sequencers such as DNBSEQ-G99."
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
-- Delivers Cutting-Edge Sequencing Platforms and Reagents to South Korea
CHEONAN, South Korea 15 September 2023 /PRNewswire=연합뉴스/ -- MGI, a company committed to building core tools and technology to lead life science, today announced MOU with Bio-Medical Science Co., Ltd. ("BMS") to expand genomics solutions in South Korea by leveraging MGI's cutting-edge technology. The MOU is expected to reach collaborations in localizing MGI's manufacturing capability in selected genetic sequencers and reagents in South Korea via BMS, which will provide the market with state-of-the-art products that have been adapted to local needs, thereby helping advance genomic research and clinical diagnostics.
"This MOU marks a key milestone for the development of genomics in South Korea as we introduce localized, high-quality and cost-effective solutions powered by our proprietary DNBSEQ™ technology." said Roy Tan, General Manager of MGI Asia Pacific. "By joining forces with our partner BMS, MGI aims to facilitate more widespread adoption of genomics, multi-omics, metagenomics and related business locally in South Korea."
Under the MOU, BMS and MGI will work to reach collaborations relating to the licensing, supply, manufacturing and distribution of selected genetic sequencers and reagents in South Korea. Leveraging BMS' strong local network for sales and distribution and MGI's innovative technology, South Korea is set to further tap into the potential of larger scale genomics, clinical studies and even microbiome.
"Amidst a rapidly growing high-throughput sequencing market in South Korea, we are noticing a mismatch between demand and supply and hope to eliminate access barriers by bringing products and solutions that are proven efficient, convenient and suited for local needs," said Kangsan D. Kim, Director of Marketing & Communications at BMS. "We are excited to partner with [PRNewswire] MGI to speed up the localization of their cutting-edge genomics products, especially sequencers such as DNBSEQ-G99."
In fact, the relationship between MGI and BMS can be traced back to 2019, when BMS became the first company in Asia Pacific to join MGI's Global Sequencer User Program (SUP) to promote the development of genetic technologies and applications through customized products and services. Earlier this year, the two companies also partnered to establish a joint Customer Experience Center (CEC) in South Korea, aiming to provide local customers with first-hand access to MGI's newer technologies and products.
About MGI
MGI Tech Co., Ltd. (or its affiliates, "MGI"), headquartered in Shenzhen, is committed to building core tools and technology to lead life science through intelligent innovation. Based on its proprietary technology, MGI focuses on research & development, production, and sales of sequencing instruments*, reagents*, and related products to support life science research, agriculture, precision medicine and healthcare. As of June 30, 2023, MGI has more than 2,800 employees, and 35.2% of whom are R&D personnel. Founded in 2016, MGI operates in more than 90 countries and regions, serving more than 2,400 customers. For more information, please visit the MGI website [https://en.mgi-tech.com/ ] or connect on Twitter [https://twitter.com/MGI_Technology ], LinkedIn [https://www.linkedin.com/company/mgi-tech688114/posts/?feedView=all&viewAsMember=true ] or YouTube [https://www.youtube.com/channel/UCKKPhGZqnAapvrt-RZ3kwig ].
About BMS
Bio-Medical Science Co. Ltd., commonly referred to as BMS, holds a prominent position in the Korean life science distribution sector. Established in 1988, its headquarter is strategically based in Gangnam, Seoul, with a network of branches and a dedicated logistics distribution center spanning the nation. Its esteemed clientele encompasses major academic and governmental institutions, along with renowned research and diagnostics centers.
*Products are provided for Research Use Only. Not for use in diagnostic procedures (except as specifically noted)
Source: MGI Tech Co., Ltd.
CONTACT: MGI PR manager, Liu Wenhui, email:liuwenhui1@mgi-tech.com
[편집자 주] 이 보도자료는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았으며, 연합뉴스의 편집방향과는 무관함을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
Copyright © 연합뉴스 보도자료. 무단전재 및 재배포 금지.
- 국회, '사상 초유' 대통령 권한대행 탄핵안 본회의 표결 | 연합뉴스
- [2025전망] 윤석열 대통령 탄핵심판 본격화…이제 '헌재의 시간' | 연합뉴스
- 오늘 윤대통령 탄핵심판 첫 기일…尹측 입장 밝힐까 | 연합뉴스
- 출석 거듭 불응한 윤대통령 이번엔 나올까…공수처 최후통첩 | 연합뉴스
- 충청·전라권 중심 많은 눈…아침 영하 10도 | 연합뉴스
- 서울 '내집' 가지려면 월급 13년 꼬박 모아야 | 연합뉴스
- [신년인터뷰] 최호정 서울시의장 "민생현장 집중…기댈 언덕 되겠다" | 연합뉴스
- 美당국자 "추락 아제르여객기, 러 방공망에 격추된 징후 있어"< 로이터 > | 연합뉴스
- 김용현측 '윗선 尹 길목 차단' 전략?…장외여론전은 닮은꼴 | 연합뉴스
- 마은혁·정계선·조한창 헌법재판관 후보자 임명동의안 국회통과 | 연합뉴스